文献速递类风湿关节炎其他结缔组织病

类风湿关节炎相关间质性肺病:推进识别与管理

Rheumatoid arthritis-associated interstitial lung disease: Advancing the identification and management.
PubMed 文献 · Semin Arthritis Rheum · 2024-11-10

本文综述类风湿关节炎相关间质性肺病(RA-ILD)的识别与管理进展,指出筛查目标为早期发现并避免不必要检查,需精准风险分层;外周生物标志物证据增长但管理证据匮乏,抗纤维化药物初期试验显示可能减缓肺功能下降,尚无菌性免疫调节治疗随机试验。

要点

  • RA-ILD筛查需精准风险分层,目前仅少数临床危险因素被认可。
  • 外周生物标志物证据增长,可能支持精准医学识别路径。
  • 抗纤维化药物初期试验显示可能减缓肺功能下降,免疫调节治疗尚无菌性随机试验。

核心结论

  • 在大型RA人群中对外周生物标志物进行稳健表征,对精准医学识别RA-ILD至关重要。
  • 考虑RA-ILD全身性质的随机治疗试验及治疗策略试验,对循证治疗RA-ILD是必要的。

研究设计与样本

  • 综述,聚焦RA-ILD识别与管理的最新研究进展及改进机会。

主要发现

  • RA-ILD筛查目标为早期发现疾病并避免不必要的检查。
  • 仅有少数被认可的RA-ILD临床危险因素,外周生物标志物证据增长可能支持精准医学路径。
  • RA-ILD诊断后管理证据匮乏;抗纤维化药物初期试验显示可能减缓肺功能下降速率,但尚无免疫调节治疗的随机试验。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出RA-ILD筛查与管理缺乏有效的循证策略。
  • 原文指出仅有少数被认可的RA-ILD临床危险因素。
  • 原文指出RA-ILD诊断后管理证据匮乏。
  • 原文指出尚无免疫调节治疗RA-ILD的随机试验。
  • 原文指出支持此类试验并解决实施障碍是高度优先事项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Interstitial lung disease (ILD) is an extra-articular manifestation of rheumatoid arthritis (RA) that causes substantial morbidity and mortality. Effective, evidence-based strategies to screen for, and manage, RA-ILD are lacking. OBJECTIVES: Highlight recent research advances in, and further opportunities to improve, the identification and management of RA-ILD. FINDINGS: The goals of RA-ILD screening are early disease detection while avoiding unnecessary testing. Such an approach requires the ability to accurate risk stratify RA patients. With only a few recognized clinical risk factors for RA-ILD, a growing body of evidence on peripheral biomarkers for RA-ILD appears well suited to support a precision medicine approach. There is a paucity of evidence to guide management after RA-ILD diagnosis. While initial trials of antifibrotics have been conducted in RA-ILD and show the potential to slow the rate of pulmonary function decline, there have been no randomized trials of immunomodulatory therapies in RA-ILD. Supporting such trials, and addressing the barriers to conducting them, is a high priority. CONCLUSION: Robust characterization of peripheral biomarkers in large, RA populations is essential to inform a precision medicine approach to RA-ILD identification. Randomized trials of treatments and treatment strategies that consider the systemic nature of RA-ILD are necessary to inform evidence-based RA-ILD treatment.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. England BR. Rheumatoid arthritis-associated interstitial lung disease: Advancing the identification and management. Semin Arthritis Rheum. 2024. PMID: 39547863. doi:10.1016/j.semarthrit.2024.152578

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。